Document Detail


Transduced p16INK4a peptides inhibit hypophosphorylation of the retinoblastoma protein and cell cycle progression prior to activation of Cdk2 complexes in late G1.
MedLine Citation:
PMID:  10363976     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Progression of cells through the G1 phase of the cell cycle requires cyclin D:Cdk4/6 and cyclin E:Cdk2 complexes; however, the duration and ordering of these complexes remain unclear. To address this, we synthesized a peptidyl mimetic of the Cdk4/6 inhibitor, p16INK4a that contained an NH2-terminal TAT protein transduction domain. Transduction of TAT-p16 wild-type peptides into cells resulted in the loss of active, hypophosphorylated pRb and elicited an early G1 cell cycle arrest, provided cyclin E:Cdk2 complexes were inactive. We conclude that cyclin D:Cdk4/6 activity is required for early G1 phase cell cycle progression up to, but not beyond, activation of cyclin E:Cdk2 complexes at the restriction point and is thus nonredundant with cyclin E:Cdk2 in late G1.
Authors:
D R Gius; S A Ezhevsky; M Becker-Hapak; H Nagahara; M C Wei; S F Dowdy
Related Documents :
15960896 - Regulating expressions of cyclin d1, prb, and anti-cancer effects of deguelin on human ...
11237006 - Can sequencing shed light on cell cycling?
20423616 - Suppression of cdk2 expression by sirna induces cell cycle arrest and cell proliferatio...
20160476 - Mutation of the dead-box helicase belle downregulates the cyclin-dependent kinase inhib...
9417046 - Heparan sulfate undergoes specific structural changes during the progression from human...
315386 - Dependence of the nucleoside effect on linear energy transfer.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Cancer research     Volume:  59     ISSN:  0008-5472     ISO Abbreviation:  Cancer Res.     Publication Date:  1999 Jun 
Date Detail:
Created Date:  1999-06-29     Completed Date:  1999-06-29     Revised Date:  2012-06-25    
Medline Journal Info:
Nlm Unique ID:  2984705R     Medline TA:  Cancer Res     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  2577-80     Citation Subset:  IM    
Affiliation:
Howard Hughes Medical Institute and Department of Pathology, Washington University School of Medicine, St. Louis, Missouri 63110, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
CDC2-CDC28 Kinases*
Cell Line
Cyclin D
Cyclin E / physiology
Cyclin-Dependent Kinase 2
Cyclin-Dependent Kinase 4
Cyclin-Dependent Kinase 6
Cyclin-Dependent Kinase Inhibitor p16 / physiology*
Cyclin-Dependent Kinases / physiology*
Cyclins / physiology*
G1 Phase / physiology*
Humans
Keratinocytes
Phosphorylation
Protein-Serine-Threonine Kinases / physiology*
Proto-Oncogene Proteins*
Retinoblastoma Protein / metabolism*
Transfection
Grant Support
ID/Acronym/Agency:
CA09547-13/CA/NCI NIH HHS; GM07200/GM/NIGMS NIH HHS
Chemical
Reg. No./Substance:
0/Cyclin D; 0/Cyclin E; 0/Cyclin-Dependent Kinase Inhibitor p16; 0/Cyclins; 0/Proto-Oncogene Proteins; 0/Retinoblastoma Protein; EC 2.7.11.1/Protein-Serine-Threonine Kinases; EC 2.7.11.22/CDC2-CDC28 Kinases; EC 2.7.11.22/CDK2 protein, human; EC 2.7.11.22/CDK4 protein, human; EC 2.7.11.22/CDK6 protein, human; EC 2.7.11.22/Cyclin-Dependent Kinase 2; EC 2.7.11.22/Cyclin-Dependent Kinase 4; EC 2.7.11.22/Cyclin-Dependent Kinase 6; EC 2.7.11.22/Cyclin-Dependent Kinases

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Identification and characterization of human MT5-MMP, a new membrane-bound activator of progelatinas...
Next Document:  Competitive and noncompetitive inhibition of the DNA-dependent protein kinase.